EU Approval Delay for Janssen’s Spravato?

Third-Party Intervention Raises EU Approval Timing Question

The EMA has received written interventions from third parties relating to its CHMP opinion that the controversial antidepressant should receive EU approval.

Question mark
• Source: Shutterstock

Something seems afoot with the EU approval of Janssen Pharmaceutical Cos.’s controversial new drug for treatment-resistant depression Spravato (esketamine).

The European Medicines Agency has received “written interventions” from third parties relating to the agency’s October recommendation that the drug...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip